Altacor is creating a leading European specialty ophthalmology company developing and marketing a portfolio of reprofiled, low-risk and/or orphan products targeting chronic eye conditions through its own specialist sales force.
The Company’s strategy is to build its product base and commercial organisation into major countries in Europe through transactions and partnerships.
Altacor’s current portfolio, which is marketed by its own sales teams in the UK, comprises seven prescription and retail ophthalmology products addressing predominantly front-of-the-eye conditions, such as Dry Eye syndrome and Blepharitis.
The Company also expects to launch a number of other hospital products in the short and medium term from its pipeline. In addition, Altacor intends to enhance its ophthalmology portfolio by in-licensing or acquiring rights to marketed or late-stage product opportunities for European sale that target important and fast-growing areas of medical need.
The global ophthalmology market is growing strongly and is expected to rise from US$18bn in 2012 to over US$23bn in 2016*. This growth is driven by the rising incidence of ocular conditions, through an ageing population, improved diagnosis, and strong demand for innovative and differentiated products.
Altacor is based in Cambridge, UK and is led by an experienced management team with strong skills in drug formulation, reprofiling and product development through its extensive network and understanding of the European regulatory environment.
*Visiongain, “Ophthalmologic Drugs: World Market Prospects 2012-2022”